Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RAPID MICRO BIOSYSTEMS, INC. (RPID)

Rapid Micro Biosystems Q2 revenue rises 11% to $8.1 million; net loss widens

Mixed Impact 3 of 5 earnings Written later

Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier, and a gross margin of 15.0%, compared with 3.8% in the prior-year quarter. The net loss widened to $12.9 million from $11.9 million, while loss per share was unchanged at $0.27, and the company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million.

Key points

  • Q2 2026 total revenue $8.1 million, up 10.9% from $7.3 million in Q2 2025
  • Net loss $12.9 million versus $11.9 million a year earlier; net loss per share $0.27 in both periods
  • Gross margin 15.0% versus 3.8% in Q2 2025; total operating expenses rose 8.9% to $13.5 million
  • Full-year 2026 revenue guidance of $37.0 million to $41.0 million reaffirmed; validation guidance raised to at least 27 from 25

The filing

CompanyRAPID MICRO BIOSYSTEMS, INC. (RPID)
Form8-K, current report
Filed with the SECAug 7, 2026, 7:02 AM ET
Accession number0001380106-26-000097

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.